Validation of an LC-MS/MS Method for the Simultaneous Intracellular Quantification of the CDK4/6 Inhibitor Abemaciclib and the EZH2 Inhibitors GSK126 and Tazemetostat

Validation of an LC-MS/MS Method for the Simultaneous Intracellular Quantification of the CDK4/6 Inhibitor Abemaciclib and the EZH2 Inhibitors GSK126 and Tazemetostat

<b>Background:</b> Inhibitors of cyclin-dependent kinases (CDKs) and epigenetic modifier enhancer of zeste homolog 2 (EZH2) have emerged as promising options in the pharmacotherapy of malignant tumors. Recently, we demonstrated synergistic antitumor effects of the CDK4/6 inhibitor abemac...

Full description

Saved in:
Bibliographic Details
Main Authors: Stefan Senekowitsch, Thomas Freitag, Daniel Dubinski, Thomas M. Freiman, Claudia Maletzki, Burkhard Hinz
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Pharmaceutics
Subjects:
LC-MS/MS
CDK4/6 inhibitor
EZH2 inhibitor
intracellular accumulation
glioblastoma cells
Online Access:https://www.mdpi.com/1999-4923/17/4/433
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1999-4923/17/4/433

Similar Items